Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588218 · ClinicalTrials.gov registry record · NA
Effect of Watermelon on Gut and Cardiometabolic Health
A NA study of Obesity and Overweight and Dysbiosis, sponsored by Florida State University.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06588218: Recruiting NA study of Obesity and Overweight and Dysbiosis, sponsored by Florida State University.
NCT06588218 is a NA study of Obesity and Overweight and Dysbiosis that is actively recruiting participants, run by Florida State University. The registered enrollment target is 36 participants, below the 464-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588218, a NA study of Obesity and Overweight and Dysbiosis, is actively recruiting participants, sponsored by Florida State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are: 1. Will consuming fresh watermelon daily for 6-weeks will improve intestinal barrier health and increase microbiome diversity such as an increased population of beneficial 'probiotic' bacteria when compared to control participants consuming a low-fat snack? 2. Will consuming fresh watermelon daily for six-weeks will improve other health measures, including body-composition, blood pressure, blood vessel function, blood lipid profiles, and measures of inflammation, as compared to control participants consuming a low-fat snack for the same time period?
Primary Outcome
Collected fecal samples will be used to determine microbiome profiles, including diversity and composition of bacteria.
Conditions Studied
Interventions
- OTHER Watermelon
- OTHER Belvita Breakfast Sandwich + 12 oz Water
Study Locations (1)
Florida
- Florida State University - Gut Biome Lab - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-10-13 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06588218 shows while recruiting
NCT06588218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 464-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Watermelon is the first listed.
NCT06588218 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06588218 about?
NCT06588218 is a clinical study titled "Effect of Watermelon on Gut and Cardiometabolic Health". The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are: 1. Will consuming fresh w...
What is the current status of trial NCT06588218?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2024-10-13. Estimated completion is 2026-08.
What conditions does trial NCT06588218 study?
This clinical trial studies the following conditions: Obesity and Overweight, Dysbiosis.
What interventions are being tested in trial NCT06588218?
The interventions under investigation include: Watermelon (OTHER), Belvita Breakfast Sandwich + 12 oz Water (OTHER).
Who is sponsoring clinical trial NCT06588218?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588218 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06588218's enrollment target sits among peer trials
36 22nd of 27 higher than 6 of 27 other Obesity and Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
-
Weight Management Intervention in College: A Pilot
RECRUITING · NA
-
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
RECRUITING · NA
-
Muscle and Movement With Anti-Obesity Medications
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI